TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00124722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Zemuron)
Description: A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide (Zemuron)
Description: A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Zemuron)
Description: A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
Study: NCT03883477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic Release
Description: Retrograde endoscopic release of the A1 pulley for treatment of trigger finger will be performed using a commercially available device by A.M. Surgical, Inc. This device has been cleared for marketing, sale and use by the U.S. Food and Drug Administration (FDA) for use as an Orthopedic manual surgical instrument based on its similarity in structure and function to previously used devices.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Open Release
Description: Standard open surgical release of the A1 pulley for treatment of trigger finger.
Study: NCT03386188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Transitory inactivation of the posterior parietal cortex and measure of sensorimotor integration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Muscle Activity (EMG)
Description: Electrodes for the collection of EMG activity will be glued on the skin next to the first interosseus dorsalis muscle, the Abductor digiti minimi, the Extensor carpi radialis and the Abductor pollicis brevis. EMG signals will be stored on computer for off-line analysis using Signal © software (Cambridge Electronic Design, Cambridge, UK)
Study: NCT00543673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk based formula A
Description: feed as per HCP directions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: #2 Standard formula
Description: Feed as per HCP directions

Intervention type: OTHER
Group type: OTHER
Intervention: #3 Human Milk
Description: Feed as per HCP directions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk based formula C
Description: Feed as per HCP direction
Study: NCT02069106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Omega LDL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01256099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-CBT for insomnia
Description: An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist guided Internet-CBT for insomnia
Description: An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Internet-CBT for insomnia, without support
Description: No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapist Guided Internet-CBT for depression
Description: An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
Study: NCT03449381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 907828
Description: Film-coated tablet
Study: NCT03188783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 tablets orally, either a single dose or twice-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 tablets orally, either a single dose or twice-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 tablets orally, either a single dose or twice-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: GDC-0853 tablets orally, either a single dose or twice-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
Study: NCT00869128

Intervention type: DRUG
Group type: OTHER
Intervention: Circadin
Description: 2 mg prolonged-release melatonin

Intervention type: DRUG
Group type: OTHER
Intervention: Circadin
Description: 2 mg prolonged-release melatonin

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT03240276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ICSI procedure for sperm injection into oocyte
Description: The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSOME
Description: Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IMSI Procedure
Description: Injection of sperm that has been selected by the MSOME method into oocytes
Study: NCT00282685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarterial bone marrow progenitor cell transplantation
Description: catheter delivery of stem cells
Study: NCT04529317

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa and quinoa-based food
Description: Products created replaced grains, legumes, tubers, also farinaceous commonly consumed by the participants and only the cereal fraction was modified, similar products based on quinoa flour were created.~Thus, apart from delivering quinoa, quinoa flakes and quinoa flour to the participants, they were given products created with ≥70% quinoa flour and were biscuits, crackers, brioche, sponge cake, baguette bread, sliced bread and pasta. Moreover, a quinoa-based recipe was delivered with eight commonly consumed recipes that replaced the tuber, legume or grain of the recipe. Each subject received the equivalent of what they consumed according to their regular diet dietary records.
Study: NCT04087369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled NCD WHO PEN Intervention
Description: In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population. In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.
Study: NCT02400619

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shock waves
Description: Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Botulinum toxin type A Botox
Study: NCT00311922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Literacy/Numeracy oriented educational intervention
Description: Comprehensive educational Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Receives comprehensive education that is not literacy/numeracy sensitive
Study: NCT04262011

Intervention type: PROCEDURE
Group type: OTHER
Intervention: immediate treatment
Description: Patients allocated to the immediate treatment group will receive full mouth treatment, and will use 0.12% chlorhexidine mouthwash, every 12 hours for a week, and will receive oral hygiene instructions throughout the follow-up period. Patients will be evaluated at the beginning, at 3 and 6 months.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: postponed treatment
Description: Patients allocated to the late treatment group will be assessed at baseline, 3 and 6 months. After the end of the follow-up period, they will receive non-surgical periodontal treatment performed in four sessions.
Study: NCT02022735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulator
Description: DBS will provide brain stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulator
Description: DBS will provide brain stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulator
Description: DBS will provide brain stimulation.
Study: NCT01136564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar
Description: 2 capsules of 1 microgram daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules daily
Study: NCT04693078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI polyp detection system based on deep learning
Description: A Polyp detection system based on deep learning and artificial intelligence, which can alert the operator in real-time to the presence and location of polyps during a colonoscopy.
Study: NCT04692116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate treatment
Description: Subthalamotomy using the ExAblate
Study: NCT01670045

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab in accordance with the licensed label recommendation.
Study: NCT03338283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromassage
Description: Electro-massage that will be performed by a specialist physiotherapist with more than 8 years of experience We use ENDOMED 482 (Enraf Nonius, Spain) for the elecro-massage. the current parameters are: frequency shift at 4000 Hz IFC, 100 Hz AMF in CV mode. We will gradually raise the current intensity until reaching a high level, but not so high as to cause pain or discomfort, nor evident muscle contraction, although a gentle vibration is allowed. The electro-massage was performed on the musculature of the shoulder and neck.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservatory treatment
Description: The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
Study: NCT00614978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib and temozolomide
Description: Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
Study: NCT03992833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung cancer screening
Description: In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume \< 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume \> 300 mm3 (positive).
Study: NCT05039125

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic cavitation
Description: * From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~* Part III: 3cm above the umbilicus to 2cm below the umbilicus~* After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~* The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~* The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~* After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic cavitation
Description: * From a standing position, each participant's abdomen was divided transversally into three sections; resulting in a total of 6 abdominal segments.~* Part III: 3cm above the umbilicus to 2cm below the umbilicus~* After washing the skin on the anterior abdominal wall with alcohol, a conducting medium (gel) was placed to the ultrasonic instrument's cavitational head.~* The gadget was turned on, a 30-minute timer was set, and the intensity was gradually increased.~* The cavitation head then moved extremely gently in a small circular motion on each abdomen section for 5 minutes.~* After completing the ultrasonic application to the six regions of the abdomen, the skin was cleansed with a piece of cotton.~For group (A): 40000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months.~For group (B):26000 HZ ultrasound was delivered for 30 minutes, 3 times/week for 2 months
Study: NCT02766036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propolis
Description: Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
Study: NCT01831271

Intervention type: OTHER
Group type: OTHER
Intervention: Prescribed physical activity
Description: Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.

Intervention type: OTHER
Group type: OTHER
Intervention: Neck specific training
Description: The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
Study: NCT00704977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique
Description: The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique
Description: The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique
Description: The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs.
Study: NCT02364076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administration of 200 mg MK-3475 once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 100mg taken by mouth twice daily
Study: NCT00420628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loteprednol etabonate/tobramycin opthalmic suspension
Description: Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
Study: NCT01372540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filanesib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04331509

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT02088892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG SSI
Description: Intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG SSI
Description: Intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG SSI
Description: Intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Tice
Description: Intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Tice
Description: Intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Tice
Description: Intradermal injection
Study: NCT00470561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Two 325 mg doses of aspirin per day for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo pills per day for 6 months
Study: NCT02193555

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A, Senofilcon A
Description: 1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A, Senofilcon A
Description: 1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
Study: NCT04839666

Intervention type: DRUG
Intervention: Propofol
Description: Perioperatively propofol administration
Study: NCT04693299

Intervention type: DIAGNOSTIC_TEST
Intervention: colonoscopy
Description: A colonoscopy scheduled within the normal pathway of care will be performed. No interventions will be performed.
Study: NCT01014195

Intervention type: OTHER
Intervention: Neurocognitive and behavioral evaluation
Description: The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.